WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
BREZTRI, already approved in over 80 countries for chronic obstructive pulmonary disease (COPD), may now offer hope to asthma sufferers. “We are excited by the positive results from the KALOS and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback